Texas ( Mar. 04, 2013) Wax Ink has issued a No Investment Interest rating for Abaxis, Inc. (Nasdaq: ABAX) based on a recent baseline equity review which placed fair value between $28-$34.

The stock closed recently at $42.96, approximately 154% above the fair value buy target for the stock and approximately 23% above the fair value close target for the stock. The recent close is 7% below analysts’ $46.00 median target for the stock.

Based on the recent close, the stock has a trailing twelve month PE of 53, and PEG Ratio of 309.

In the past 52 weeks, share prices have moved between a high of $44.98 and a low of $26.11. With the recent $42.96 close, the stock is trading 5% below the 52 week high and 39% above the 52 week low.

Abaxis, Inc. manufacturers portable blood analysis systems for use in human and veterinary blood constituent measurements.

All valuations are based on the listed company’s most recent SEC annual filing, and all prices are per share.

Wax Ink is a baseline equity research company comprised of individual investors, NOT licensed or registered with ANY government agency.

Comments

Powered by Facebook Comments

Similar Posts: ABAX | Abaxis Inc. | Diagnostic Substances | Healthcare

RSS feeds: ABAX | Abaxis Inc. | Diagnostic Substances | Healthcare |

Other Posts by Shawn | RSS Feed for this author